Lung Cancer Trial, Recruiting NCT07401615 Sponsor: Istituto Clinico Humanitas Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07401615
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have inoperable (cannot be surgically removed) primary non-small cell lung cancer, or cancer that has spread to the lungs from elsewhere, and who have already been treated with a focused, high-dose radiation treatment called SBRT
  • People whose cancer has come back in the same area (overlapping where the original radiation was aimed), confirmed by scans or tissue biopsy, within the chest
  • People whose previous SBRT treatment used a radiation dose at or above a certain high level (biologically equivalent dose of 75 Gy or higher)
  • People who are receiving a repeat course of focused, high-dose radiation (up to 8 sessions) aimed at eliminating the cancer
  • People who either have no cancer that has spread to distant parts of the body, or whose distant spread is considered stable and controlled at the time of re-treatment
  • People whose previous SBRT treatment was completed more than 12 months ago
  • People who have a general health and activity level rated at 2 or below on a standard medical scale (meaning they are able to care for themselves but may not be able to do heavy physical work) (confirm with trial site)

Who may not be able to join:

  • People who have previously received conventional (standard, non-focused) radiation therapy to the area
  • People whose repeat radiation treatment is planned at lower, palliative doses (aimed at relieving symptoms rather than eliminating the cancer)
  • People whose repeat radiation treatment uses a conventional or only mildly reduced fractionation schedule, rather than the high-dose, short-course approach used in this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 0282247428

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Istituto Clinico Humanitas
Registry
ClinicalTrials.gov
Start date
25 November 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov